Medical and Pharmaceutical Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S. The stock opened at USD$8.54 and traded as high as USD$8.59 before dipping briefly to USD$4.20 before ending the day at USD$8.52 Joseph MortonAugust 5, 2025
Medical and Pharmaceutical Lantern Pharma completes Japanese enrolment for lung cancer drug trial Japan has an extremely high rate of non-smokers getting diagnosed with the disease Rowan DunneAugust 5, 2025
AI and Autonomy Offline AI tool could transform skin cancer diagnosis in remote areas Ensuring the system's resilience in low-resource environments has been a core design priority Joseph MortonJuly 30, 2025
AI and Autonomy New Lyme test detects disease early with 90% accuracy It uses a machine-learning algorithm to analyze the immune response, detecting patterns unique to each individual Joseph MortonJuly 29, 2025
Medical and Pharmaceutical Hong Kong lung cancer survivor advocates for AI-powered screening measures Artificial intelligence has the power to cut healthcare costs associated with lung cancer screening in half, he highlighted Rowan DunneJuly 28, 2025
Crypto/Blockchain Liminatus Pharma shares spike 26% on Digital Asset focused capital raise plans The engagement builds upon Liminatus’s previously announced review of a blockchain-integrated treasury strategy Joseph MortonJuly 24, 2025
Medical and Pharmaceutical Lung cancer survivor & spouse use wood ribbons to promote disease awareness The White Ribbon Project aims to draw attention to how anyone can be diagnosed with the condition Rowan DunneJuly 24, 2025
Medical and Pharmaceutical bioAffinity Technologies obtains Canadian patent for lung cancer spit test The CyPath Lung screening tool is also patented in China, Australia and Japan Rowan DunneJuly 22, 2025
Medical and Pharmaceutical Medpace Holdings stock just popped by 50%, but why? Medpace delivered a standout Q2, with revenue rising 14.2 per cent year-over-year to USD$603.3 million Joseph MortonJuly 22, 2025
Medical and Pharmaceutical Whoop on the FDA hot seat for not following marketing rules The FDA maintains that blood pressure estimation is not a low-risk function Joseph MortonJuly 21, 2025